Table of contents
Editorials
Time for leadership - p821
doi:10.1038/nbt0807-821
Abstract - Time for leadership | Full Text - Time for leadership | PDF (118 KB) - Time for leadership
Patenting the parts - p822
doi:10.1038/nbt0807-822
Abstract - Patenting the parts | Full Text - Patenting the parts | PDF (60 KB) - Patenting the parts
News
Positive clinical data in Parkinson's and ischemia buoy gene therapy - pp823 - 824
Cormac Sheridan
doi:10.1038/nbt0807-823
Abstract - Positive clinical data in Parkinson's and ischemia buoy gene therapy | Full Text - Positive clinical data in Parkinson's and ischemia buoy gene therapy | PDF (210 KB) - Positive clinical data in Parkinson's and ischemia buoy gene therapy
Clinical setbacks for toll-like receptor 9 agonists in cancer - pp825 - 826
Charlie Schmidt
doi:10.1038/nbt0807-825
Abstract - Clinical setbacks for toll-like receptor 9 agonists in cancer | Full Text - Clinical setbacks for toll-like receptor 9 agonists in cancer | PDF (141 KB) - Clinical setbacks for toll-like receptor 9 agonists in cancer
Uncertainty surrounds cancer vaccine review at FDA - pp827 - 828
Jeffrey L Fox
doi:10.1038/nbt0807-827
Abstract - Uncertainty surrounds cancer vaccine review at FDA | Full Text - Uncertainty surrounds cancer vaccine review at FDA | PDF (82 KB) - Uncertainty surrounds cancer vaccine review at FDA
Ann Arbor community rallies in wake of Pfizer shutdown - pp829 - 830
Catherine Shaffer
doi:10.1038/nbt0807-829
Abstract - Ann Arbor community rallies in wake of Pfizer shutdown | Full Text - Ann Arbor community rallies in wake of Pfizer shutdown | PDF (318 KB) - Ann Arbor community rallies in wake of Pfizer shutdown
In Brief
News in brief - pp831 - 832
doi:10.1038/nbt0807-831
Data Page
IPOs break $1 billion in Q2 - p833
Stacy Lawrence
doi:10.1038/nbt0807-833
Full Text - IPOs break $1 billion in Q2 | PDF (174 KB) - IPOs break $1 billion in Q2
News Features
China syndrome—a regulatory framework in meltdown? - pp835 - 837
Hepeng Jia
doi:10.1038/nbt0807-835
Abstract - China syndrome[mdash]a regulatory framework in meltdown? | Full Text - China syndrome—a regulatory framework in meltdown? | PDF (212 KB) - China syndrome—a regulatory framework in meltdown?
Stroke treatment—light at the end of the tunnel? - pp838 - 840
Ken Garber
doi:10.1038/nbt0807-838
Abstract - Stroke treatment[mdash]light at the end of the tunnel? | Full Text - Stroke treatment—light at the end of the tunnel? | PDF (255 KB) - Stroke treatment—light at the end of the tunnel?
Opinion and Comment
Correspondence
Realism about PDB - pp845 - 846
Helen M Berman, Kim Henrick, Haruki Nakamura, John Markley, Philip E Bourne & John Westbrook
doi:10.1038/nbt0807-845
Full Text - Realism about PDB | PDF (150 KB) - Realism about PDB
Realism about PDB - p846
doi:10.1038/nbt0807-846a
Full Text - Realism about PDB | PDF (87 KB) - Realism about PDB
The Metabolomics Standards Initiative - pp846 - 848
MSI Board Members:
doi:10.1038/nbt0807-846b
Full Text - The Metabolomics Standards Initiative | PDF (281 KB) - The Metabolomics Standards Initiative
Dichotomy in post-genomic microbiology - pp848 - 849
Giovanna E Felis, Douwe Molenaar, Franco Dellaglio & Johan E T van Hylckama Vlieg
doi:10.1038/nbt0807-848
Full Text - Dichotomy in post-genomic microbiology | PDF (180 KB) - Dichotomy in post-genomic microbiology | Supplementary information
Novel leverage of structural genomics - pp849 - 851
Jinfeng Liu, Gaetano T Montelione & Burkhard Rost
doi:10.1038/nbt0807-849
Full Text - Novel leverage of structural genomics | PDF (259 KB) - Novel leverage of structural genomics | Supplementary information
Commentary
When less is more - pp853 - 857
Bruce L Booth
doi:10.1038/nbt0807-853
Abstract - When less is more | Full Text - When less is more | PDF (252 KB) - When less is more | Supplementary information
Features
A better prescription for drug-development financing - pp859 - 866
Mark Kessel & Frederick Frank
doi:10.1038/nbt0807-859
Abstract - A better prescription for drug-development financing | Full Text - A better prescription for drug-development financing | PDF (722 KB) - A better prescription for drug-development financing
Patents
Changing patent strategies: what will they mean for the industry? - pp867 - 868
Ann E Mills & Patti M Tereskerz
doi:10.1038/nbt0807-867
Abstract - Changing patent strategies: what will they mean for the industry? | Full Text - Changing patent strategies: what will they mean for the industry? | PDF (97 KB) - Changing patent strategies: what will they mean for the industry?
Recent patent applications in drug screening - p869
doi:10.1038/nbt0807-869
Full Text - Recent patent applications in drug screening | PDF (41 KB) - Recent patent applications in drug screening
News and Views
A human hepatocyte factory - pp871 - 872
David A Shafritz
doi:10.1038/nbt0807-871
Abstract - A human hepatocyte factory | Full Text - A human hepatocyte factory | PDF (807 KB) - A human hepatocyte factory
See also: Research by Azuma et al.
Rescuing ancient DNA - pp872 - 874
M Thomas P Gilbert & Eske Willerslev
doi:10.1038/nbt0807-872
Abstract - Rescuing ancient DNA | Full Text - Rescuing ancient DNA | PDF (175 KB) - Rescuing ancient DNA
See also: Letter by d'Abbadie et al.
The ABCs of low-phytate crops - pp874 - 875
Victor Raboy
doi:10.1038/nbt0807-874
Abstract - The ABCs of low-phytate crops | Full Text - The ABCs of low-phytate crops | PDF (155 KB) - The ABCs of low-phytate crops
See also: Research by Shi et al.
Antibodies cut down to size - pp875 - 877
Robert Charles Ladner
doi:10.1038/nbt0807-875
Abstract - Antibodies cut down to size | Full Text - Antibodies cut down to size | PDF (350 KB) - Antibodies cut down to size
See also: Research by Qiu et al.
Reprogramming by the numbers - pp877 - 878
Shin-ichi Nishikawa
doi:10.1038/nbt0807-877
Abstract - Reprogramming by the numbers | Full Text - Reprogramming by the numbers | PDF (352 KB) - Reprogramming by the numbers
Gene expression analysis goes digital - pp878 - 880
Victor E Velculescu & Kenneth W Kinzler
doi:10.1038/nbt0807-878
Abstract - Gene expression analysis goes digital | Full Text - Gene expression analysis goes digital | PDF (2,117 KB) - Gene expression analysis goes digital
Research highlights - p881
doi:10.1038/nbt0807-881
Full Text - Research highlights | PDF (102 KB) - Research highlights
Computational Biology
Primer
How does eukaryotic gene prediction work? - pp883 - 885
Michael R Brent
doi:10.1038/nbt0807-883
Abstract - How does eukaryotic gene prediction work? | Full Text - How does eukaryotic gene prediction work? | PDF (200 KB) - How does eukaryotic gene prediction work?
Research
Perspective
The minimum information about a proteomics experiment (MIAPE) - pp887 - 893
Chris F Taylor, Norman W Paton, Kathryn S Lilley, Pierre-Alain Binz, Randall K Julian, Jr, Andrew R Jones, Weimin Zhu, Rolf Apweiler, Ruedi Aebersold, Eric W Deutsch, Michael J Dunn, Albert J R Heck, Alexander Leitner, Marcus Macht, Matthias Mann, Lennart Martens, Thomas A Neubert, Scott D Patterson, Peipei Ping, Sean L Seymour, Puneet Souda, Akira Tsugita, Joel Vandekerckhove, Thomas M Vondriska, Julian P Whitelegge, Marc R Wilkins, Ioannnis Xenarios, John R Yates, III & Henning Hermjakob
doi:10.1038/nbt1329
Abstract - The minimum information about a proteomics experiment (MIAPE) | Full Text - The minimum information about a proteomics experiment (MIAPE) | PDF (291 KB) - The minimum information about a proteomics experiment (MIAPE)
The minimum information required for reporting a molecular interaction experiment (MIMIx) - pp894 - 898
Sandra Orchard, Lukasz Salwinski, Samuel Kerrien, Luisa Montecchi-Palazzi, Matthias Oesterheld, Volker Stümpflen, Arnaud Ceol, Andrew Chatr-aryamontri, John Armstrong, Peter Woollard, John J Salama, Susan Moore, Jérôme Wojcik, Gary D Bader, Marc Vidal, Michael E Cusick, Mark Gerstein, Anne-Claude Gavin, Giulio Superti-Furga, Jack Greenblatt, Joel Bader, Peter Uetz, Mike Tyers, Pierre Legrain, Stan Fields, Nicola Mulder, Michael Gilson, Michael Niepmann, Lyle Burgoon, Javier De Las Rivas, Carlos Prieto, Victoria M Perreau, Chris Hogue, Hans-Werner Mewes, Rolf Apweiler, Ioannis Xenarios, David Eisenberg, Gianni Cesareni & Henning Hermjakob
doi:10.1038/nbt1324
Abstract - The minimum information required for reporting a molecular interaction experiment (MIMIx) | Full Text - The minimum information required for reporting a molecular interaction experiment (MIMIx) | PDF (235 KB) - The minimum information required for reporting a molecular interaction experiment (MIMIx) | Supplementary information
Brief Communications
Enrichment of tomato flavor by diversion of the early plastidial terpenoid pathway - pp899 - 901
Rachel Davidovich-Rikanati, Yaron Sitrit, Yaakov Tadmor, Yoko Iijima, Natalya Bilenko, Einat Bar, Bentsi Carmona, Elazar Fallik, Nativ Dudai, James E Simon, Eran Pichersky & Efraim Lewinsohn
doi:10.1038/nbt1312
First paragraph - Enrichment of tomato flavor by diversion of the early plastidial terpenoid pathway | Full Text - Enrichment of tomato flavor by diversion of the early plastidial terpenoid pathway | PDF (178 KB) - Enrichment of tomato flavor by diversion of the early plastidial terpenoid pathway | Supplementary information
Articles
Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice - pp903 - 910
Hisaya Azuma, Nicole Paulk, Aarati Ranade, Craig Dorrell, Muhsen Al-Dhalimy, Ewa Ellis, Stephen Strom, Mark A Kay, Milton Finegold & Markus Grompe
doi:10.1038/nbt1326
Abstract - Robust expansion of human hepatocytes in : Fah: -/-: /: Rag2: -/-: /: Il2rg: -/-: mice | Full Text - Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice | PDF (761 KB) - Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice | Supplementary information
See also: News and Views by Shafritz
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells - pp911 - 920
Farbod Shojaei, Xiumin Wu, Ajay K Malik, Cuiling Zhong, Megan E Baldwin, Stefanie Schanz, Germaine Fuh, Hans-Peter Gerber & Napoleone Ferrara
doi:10.1038/nbt1323
Abstract - Tumor refractoriness to anti-: VEGF: treatment is mediated by CD11b: +: Gr1: +: myeloid cells | Full Text - Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells | PDF (383 KB) - Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells | Supplementary information
Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting - pp921 - 929
Xiao-Qing Qiu, He Wang, Bei Cai, Lan-Lan Wang & Shi-Tao Yue
doi:10.1038/nbt1320
Abstract - Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting | Full Text - Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting | PDF (509 KB) - Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting | Supplementary information
See also: News and Views by Ladner
Embryo-specific silencing of a transporter reduces phytic acid content of maize and soybean seeds - pp930 - 937
Jinrui Shi, Hongyu Wang, Kathleen Schellin, Bailin Li, Marianna Faller, Johan M Stoop, Robert B Meeley, David S Ertl, Jerry P Ranch & Kimberly Glassman
doi:10.1038/nbt1322
Abstract - Embryo-specific silencing of a transporter reduces phytic acid content of maize and soybean seeds | Full Text - Embryo-specific silencing of a transporter reduces phytic acid content of maize and soybean seeds | PDF (263 KB) - Embryo-specific silencing of a transporter reduces phytic acid content of maize and soybean seeds | Supplementary information
See also: News and Views by Raboy
Letter
Molecular breeding of polymerases for amplification of ancient DNA - pp939 - 943
Marc d'Abbadie, Michael Hofreiter, Alexandra Vaisman, David Loakes, Didier Gasparutto, Jean Cadet, Roger Woodgate, Svante Pääbo & Philipp Holliger
doi:10.1038/nbt1321
First paragraph - Molecular breeding of polymerases for amplification of ancient DNA | Full Text - Molecular breeding of polymerases for amplification of ancient DNA | PDF (335 KB) - Molecular breeding of polymerases for amplification of ancient DNA | Supplementary information
See also: News and Views by Gilbert & Willerslev
Corrigendum
Corrigendum: Therapeutic targeting of a stem cell niche - p944
Gregor B Adams, Roderick P Martin, Ian R Alley, Karissa T Chabner, Kenneth S Cohen, Laura M Calvi, Henry M Kronenberg & David T Scadden
doi:10.1038/nbt0807-944b
Full Text - Corrigendum: Therapeutic targeting of a stem cell niche | PDF (51 KB) - Corrigendum: Therapeutic targeting of a stem cell niche
Naturejobs
Careers and Recruitment
Mission possible: managing innovation in drug discovery - pp945 - 946
Xiaotian Zhong & George B Moseley, III
doi:10.1038/nbt0807-945
Abstract - Mission possible: managing innovation in drug discovery | Full Text - Mission possible: managing innovation in drug discovery | PDF (184 KB) - Mission possible: managing innovation in drug discovery
